Related Experiment Video
Updated: Jan 7, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Glutaminergic Modulators as Potential Therapeutic Modalities for Neuropathic Pain
Butchi Raju Akondi1, Siva Reddy Challa2, Ramya Bandarupalli3
1Department of Clinical Pharmacy and Pharmacology, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia.
None:
Chronic neuropathic pain due to injury or dysfunction of the nervous system, which intensifies as it continues, affects millions of people and remains a formidable treatment challenge in spite of a growing range of medication choices. This neuropathy can range from mild to extreme in pain levels. In spite of several experimental and animal studies on neuropathic pain, its pathophysiologic mechanisms have not been completely understood. The pharmacotherapy for neuropathic pain has had a limited success with little or no response to commonly-used pain-reducing drugs, such as nonsteroidal anti-inflammatory drugs and opiates. Recent research efforts into pathophysiological mechanisms have revealed new treatment targets, new classification schemes have opened up novel options for individualized treatment strategies, and the implementation of several international guidelines should help to improve care of patients. This review briefly summarizes the theoretical development and experimental evidence of recent and novel emerging drug target the glutaminergic system, for neuropathic pain treatment. Sustained efforts on this novel drug target can expedite the development of lead compounds to reach the clinical stage, which will broaden our pharmacotherapeutic armaments against various debilitating, painful conditions.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Analgesia and Pain Management
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Opioid Analgesics: Synthetic and Semisynthetic Opioids

